Biostem Technologies (BSEM) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $82.6 million, marking the third consecutive quarter of record growth and positive GAAP net income of $6.8 million.

• Net revenue for the first nine months of 2024 reached $199 million, driven by strong demand for AmnioWrap2Ⓡ and successful commercialization of placental-derived biologics.

• Gross margin held at 94.9%–95%, reflecting operational efficiency and manufacturing excellence.

• Strategic partnerships and expanded distribution agreements, notably with Venture Medical, supported nationwide launches and upcoming product introductions.

• Filed Form 10 with the SEC and submitted a Nasdaq uplisting application to enhance visibility and investor access.

Financial highlights

• Q3 2024 net revenue was $82.6 million, up from $3.5 million in Q3 2023, a 2,259% increase.

• Gross profit for Q3 was $78.3 million (94.9%–95% margin), up from $3.2 million (90.7%–91%) in Q3 2023.

• Operating expenses for Q3 were $69 million, up from $4.5 million in Q3 2023, mainly due to workforce expansion and distributor fees.

• Net income for Q3 was $6.8 million; adjusted EBITDA was $9.9 million.

• Cash balance increased to $14.6 million at September 30, 2024, up from $239,000 at year-end.

Outlook and guidance

• Optimistic about upcoming clinical trial results and broadening market access, which could drive further payer coverage and adoption.

• Expanded distribution agreement in October 2024 to include additional product lines.

• Manufacturing capacity expansion expected to be operational in the second half of 2024.

• CMS confirmed ASP plus 6% pricing for 2025, supporting pricing stability.

• Strategic initiatives, including Nasdaq uplisting, are expected to accelerate growth and shareholder value.